
Vikram Mathews

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2115758/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Gene Therapy, 2023, 30, 216-221.	4.5	6
2	Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma—A Single Center Experience. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 290-298.	0.6	1
3	Impact of donor telomere length on survival in patients undergoing matched sibling donor transplantation for aplastic anaemia. British Journal of Haematology, 2022, 196, 724-734.	2.5	2
4	Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood Advances, 2022, 6, 652-663.	5.2	4
5	Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complications–A single center experience from India. Transplantation and Cellular Therapy, 2022, 28, 45.e1-45.e8.	1.2	6
6	Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia. Blood Cancer Journal, 2022, 12, 22.	6.2	8
7	BK polyomavirus hemorrhagic cystitis in hematopoietic cell transplant recipients. Journal of Global Infectious Diseases, 2022, 14, 17.	0.5	6
8	Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. American Journal of Hematology, 2022, 97, 514-518.	4.1	30
9	Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?. International Journal of Cancer, 2022, 150, 1401-1411.	5.1	14
10	Myeloproliferative neoplasms â \in " a global view. British Journal of Haematology, 2022, , .	2.5	3
11	Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning. Transplantation and Cellular Therapy, 2022, 28, 356.e1-356.e6.	1.2	2
12	Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 615-622.	0.6	4
13	In utero origin of myelofibrosis presenting in adult monozygotic twins. Nature Medicine, 2022, 28, 1207-1211.	30.7	26
14	Safety of peripheral blood stem cell harvest in children under anaesthesia in the day care setting – A single centre experience. Transfusion and Apheresis Science, 2021, 60, 102962.	1.0	1
15	Primary Immunodeficiencies in India: Molecular Diagnosis and the Role of Next-Generation Sequencing. Journal of Clinical Immunology, 2021, 41, 393-413.	3.8	17
16	Management of relapse in acute promyelocytic leukaemia treated with upâ€front arsenic trioxideâ€based regimens. British Journal of Haematology, 2021, 192, 292-299.	2.5	13
17	Outcome of iron reduction therapy in ex-thalassemics. PLoS ONE, 2021, 16, e0238793.	2.5	3
18	BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib. Leukemia and Lymphoma, 2021, 62, 1528-1531.	1.3	1

#	Article	IF	CITATIONS
19	Evolving Chemotherapy Free Regimens for Acute Promyelocytic Leukemia. Frontiers in Oncology, 2021, 11, 621566.	2.8	7
20	Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). British Journal of Haematology, 2021, 193, e1-e4.	2.5	9
21	Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	2
22	Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia. International Journal of Laboratory Hematology, 2021, 43, 658-663.	1.3	5
23	An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia. Transplantation and Cellular Therapy, 2021, 27, 409.e1-409.e6.	1.2	7
24	NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1303-1313.	0.7	0
25	Real World Data of Concurrent Arsenic Trioxide and All-Trans Retinoic Acid with Minimal Use of Anthracycline in the Treatment of Acute Promyelocytic Leukemia. Blood, 2021, 138, 2338-2338.	1.4	1
26	Germline Variants Contribute Significantly to the Pathogenesis of Aplastic Anemia in India. Blood, 2021, 138, 1105-1105.	1.4	0
27	Endothelial Activation and Stress Index (EASIX) Measured Pre-Transplant Identifies a Subgroup with High Transplant Related Mortality in Patients with Thalassemia Undergoing Stem Cell Transplantation Using Thiotepa-Treosulfan-Fludarabine Conditioning. Blood, 2021, 138, 1781-1781.	1.4	0
28	Arsenic Trioxide Reprograms the Bone-Marrow Microenvironment to Sensitize Minimal Residual Disease in Acute Myeloid Leukemia. Blood, 2021, 138, 1166-1166.	1.4	0
29	Haploidentical Natural Killer Cell Therapy As an Adjunct to Stem Cell Transplantation for Refractory Acute Myeloid Leukemia. Blood, 2021, 138, 3827-3827.	1.4	1
30	Combining Arsenic Trioxide and Mitocans Selectively Disrupts Cellular Energetics in Acute Myeloid Leukemia. Blood, 2021, 138, 2245-2245.	1.4	0
31	Genetic Ablation of Nuclear Receptor Interacting Protein 1 (NRIP1) Sensitizes Acute Myeloid Leukemia Cells to Retinoic Acids. Blood, 2021, 138, 1146-1146.	1.4	1
32	Endocrine Challenges and Metabolic Profile in Recipients of Allogeneic Haematopoietic Stem Cell Transplant: A Cross-Sectional Study from Southern India. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 484-490.	0.6	1
33	Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 130-135.e1.	0.4	2
34	Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 71-77.	0.6	7
35	A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 97-103.	0.6	4
36	Do Bone Density, Bone Microarchitecture, and Body Composition Differ in Recipients of Allogeneic Hematopoietic Stem Cell Transplant? A Cross-Sectional Study from Southern India. Biology of Blood and Marrow Transplantation, 2020, 26, 540-545.	2.0	2

#	Article	IF	CITATIONS
37	Screening of genetic variants in ELANE mutation negative congenital neutropenia by next generation sequencing. Journal of Clinical Pathology, 2020, 73, 322-327.	2.0	1
38	Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting. British Journal of Haematology, 2020, 188, 930-934.	2.5	2
39	Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide. British Journal of Haematology, 2020, 189, 269-278.	2.5	4
40	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
41	Prognostic value of MRD monitoring based on <i>BCR-ABL1</i> copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 3468-3475.	1.3	4
42	Prognostic plasma biomarkers of early complications and graftâ€versusâ€host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. EJHaem, 2020, 1, 219-229.	1.0	10
43	Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients. Scientific Reports, 2020, 10, 20640.	3.3	9
44	How I treat advanced Hodgkin lymphoma — a global view. British Journal of Haematology, 2020, 190, 837-850.	2.5	7
45	Drugâ€resistant organisms are common in fecal surveillance cultures, predict bacteremia and correlate with poorer outcomes in patients undergoing allogeneic stem cell transplants. Transplant Infectious Disease, 2020, 22, e13273.	1.7	11
46	A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. Cancer Medicine, 2020, 9, 2603-2610.	2.8	14
47	Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells. Molecular Cancer Research, 2020, 18, 529-536.	3.4	10
48	MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Medicine, 2020, 9, 4512-4526.	2.8	39
49	JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis. Annals of Hematology, 2020, 99, 983-989.	1.8	10
50	TARGET: a survey of realâ€world management of chronic myeloid leukaemia across 33 countries. British Journal of Haematology, 2020, 190, 869-876.	2.5	40
51	Ehl Factors at Lower Than Standard Dose Achieve Satisfactory Surgical Haemostatsis in Haemophilia. Blood, 2020, 136, 25-26.	1.4	0
52	Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantation—A Single Centre Experience. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 215-222.	0.6	10
53	Outcomes Following Allogeneic Stem Cell Transplantation Using Non-sibling Family Donors. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 43-49.	0.6	4
54	Molecular characterization of novel Adeno-associated virus variants infecting human tissues. Virus Research, 2019, 272, 197716.	2.2	3

#	Article	IF	CITATIONS
55	A personalized approach to acute myeloid leukemia therapy: current options. Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 167-179.	0.7	7
56	Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia. Cell Death and Disease, 2019, 10, 736.	6.3	31
57	Summary of the Highlights of 2019 ASTCT Meeting by iNDUS BMT Group at Chennai, India. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 409-415.	0.6	1
58	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019, 133, 1630-1643.	1.4	393
59	Evaluation of nonneutralizing antibodies against factor VIII in severe haemophilia A patients from India. Blood Coagulation and Fibrinolysis, 2019, 30, 337-340.	1.0	3
60	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	5.2	37
61	Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Advances, 2019, 3, 2562-2570.	5.2	48
62	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2019, 25, 488-495.	2.0	21
63	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
64	Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population. Haemophilia, 2019, 25, 67-74.	2.1	9
65	Heterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD). Indian Journal of Hematology and Blood Transfusion, 2019, 35, 223-232.	0.6	5
66	Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). Blood, 2019, 134, 1306-1306.	1.4	6
67	Induction Related Mortality in Acute Myeloid Leukemia: Multivariate Model of Predictive Score from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). Blood, 2019, 134, 2615-2615.	1.4	13
68	Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia. Blood, 2019, 134, 3272-3272.	1.4	1
69	Targeting Extracellular Vesicle Secretion As a Strategy to Overcome Microenvironment Mediated Drug Resistance in Acute Myeloid Leukemia. Blood, 2019, 134, 3733-3733.	1.4	1
70	Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts. Blood, 2019, 134, 4537-4537.	1.4	0
71	Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT. Blood, 2019, 134, 1977-1977.	1.4	0
72	Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Pharmacology and Therapeutics, 2018, 104, 575-583.	4.7	22

5

#	Article	IF	CITATIONS
73	Mechanisms and management of coagulopathy in acute promyelocytic leukemia. Thrombosis Research, 2018, 164, S82-S88.	1.7	32
74	APL in Developing Countries: ATO-Based Approach. , 2018, , 217-229.		0
75	Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2018, 24, 103-108.	2.0	9
76	Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 494-500.	2.0	22
77	Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country. Journal of Global Oncology, 2018, 4, 1-12.	0.5	12
78	Spectrum of <i>ELANE</i> mutations in congenital neutropenia: a single-centre study in patients of Indian origin. Journal of Clinical Pathology, 2018, 71, 1046-1050.	2.0	8
79	Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. Frontiers in Immunology, 2018, 9, 1357.	4.8	14
80	Allele Specific PCR: A Cost Effective Screening Method for MPL Mutations in Myeloproliferative Neoplasms. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 765-767.	0.6	6
81	A Low Incidence of Cytomegalo Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation Despite a High Seroprevalence. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 636-642.	0.6	6
82	Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, e31-e35.	2.0	18
83	Related and Unrelated Donor Transplantation for \hat{I}^2 Thalassemia Major: Results of an International Survey. Blood, 2018, 132, 308-308.	1.4	1
84	Very Long Term Follow-up Data of Pediatric Acute Promyelocytic Leukemia Treated with Upfront Arsenic-Trioxide Based Regimens. Blood, 2018, 132, 1400-1400.	1.4	3
85	Myeloproliferative Neoplasms in Asia, Including Middle East, Turkey, and Algeria: Epidemiological Indices and Treatment Practice Patterns from the Multinational, Multicenter, Observational MERGE Registry. Blood, 2018, 132, 5461-5461.	1.4	1
86	Higher Incidence of Graft Rejection in Non-Sibling Fully Matched Related Donor Stem Cell Transplants for Thalassemia Major: A Cautionary Note. Blood, 2018, 132, 2178-2178.	1.4	4
87	Hematological Cancer Consortium: Multi-Center Acute Myeloid Leukemia Registry Data from India. Blood, 2018, 132, 4006-4006.	1.4	4
88	Haplo-Identical Transplants Using Post Transplant Cyclophosphamide (PTCy) Are Associated with Good Outcomes If Transplanted with Early Disease - a Single Centre Analysis from India. Blood, 2018, 132, 4652-4652.	1.4	2
89	Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate — Recombinant Factor VIII Fc (Eloctate™) — a Report from India. Blood, 2018, 132, 2494-2494.	1.4	2
90	Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 503.	0.2	1

#	Article	IF	CITATIONS
91	Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India. Indian Journal of Medical Research, 2018, 147, 464.	1.0	5
92	Iron Reduction Therapy in Ex-Thalassemics - Long Term Outcome. Blood, 2018, 132, 4591-4591.	1.4	0
93	Targeted IV Vs Oral Busulfan in Very Young Children with Thalassemia Major Undergoing Matched Allogeneic Haematopoietic Stem Cell Transplantation. Blood, 2018, 132, 5707-5707.	1.4	0
94	Hematological Cancer Consortium: Multi-Center Acute Lymphoblastic Leukemia Registry Data from India. Blood, 2018, 132, 1374-1374.	1.4	0
95	Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry. Blood, 2018, 132, 4311-4311.	1.4	4
96	Management of Relapse in Acute Promyelocytic Leukemia Treated with Upfront Arsenic Trioxide Based Regimens. Blood, 2018, 132, 666-666.	1.4	3
97	ATP-binding casette transporter expression in acute myeloid leukemia: association with <i>in vitro</i> cytotoxicity and prognostic markers. Pharmacogenomics, 2017, 18, 235-244.	1.3	24
98	The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 126-134.	0.9	8
99	APL: Oh! What a tangled web we weave. Blood, 2017, 129, 1744-1745.	1.4	0
100	Invasive fungal infection following chemotherapy for acute myeloid leukaemia—Experience from a developing country. Mycoses, 2017, 60, 686-691.	4.0	26
101	Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. Blood Cells, Molecules, and Diseases, 2017, 66, 37-46.	1.4	7
102	Allogeneic stem cell transplantation for thalassemia major in India. Pediatric Hematology Oncology Journal, 2017, 2, 114-120.	0.1	7
103	Establishing a comprehensive diagnosis of primary immunodeficiency diseases. Blood Advances, 2017, 1, 39-41.	5.2	0
104	Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India. Journal of Global Oncology, 2017, 3, 773-781.	0.5	15
105	Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS ONE, 2017, 12, e0177227.	2.5	61
106	Allogeneic Stem Cell Transplantation for Thalassemia Major. , 2017, , 343-357.		2
107	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget, 2017, 8, 41620-41630.	1.8	1
108	Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children. Annals of Hematology, 2016, 95, 1429-1434.	1.8	56

#	Article	IF	CITATIONS
109	Treatment rates of paediatric acute myeloid leukaemia: a view from three tertiary centres in India – response to Gupta <i>etÂal</i> . British Journal of Haematology, 2016, 175, 347-349.	2.5	3
110	Role of endovascular embolization in treatment of acute bleeding complications in haemophilia patients. British Journal of Radiology, 2016, 89, 20151064.	2.2	5
111	Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 78, 1051-1058.	2.3	20
112	Clinical, Hematological and Molecular Analysis of Homozygous Hb E (<i>HBB</i> : c.79G > A) in the Indian Population. Hemoglobin, 2016, 40, 16-19.	0.8	4
113	Leukocyte Adhesion Deficiency-I: Clinical and Molecular Characterization in an Indian Population. Indian Journal of Pediatrics, 2016, 83, 799-804.	0.8	14
114	Atypical <i>BCR-ABL1</i> fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. Leukemia and Lymphoma, 2016, 57, 2481-2484.	1.3	5
115	Metabolic Rewiring Drives Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia. Blood, 2016, 128, 3956-3956.	1.4	5
116	Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition. Blood, 2016, 128, 446-446.	1.4	1
117	Role of miRNA in Micro-Environment Mediated Drug Resistance in Acute Promyelocytic Leukemia to Arsenic Trioxide. Blood, 2016, 128, 5125-5125.	1.4	1
118	A 5'UTR Polymorphism in NT5E Gene Influences Outcome in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine Based Conditioning Regimen. Blood, 2016, 128, 984-984.	1.4	2
119	Osteoblast Differentiation of Stromal Cells Induced By Leukemic Cells. Blood, 2016, 128, 5062-5062.	1.4	0
120	Alteration of the Hematopoietic Components, Mesenchymal Stromal Cells and Vascular Elements in the Bone Marrow Niche in Myelodysplastic Syndrome: Refractory Cytopenia with Multilineage Dysplasia. Blood, 2016, 128, 5516-5516.	1.4	0
121	Fate of Ikaros in Multiple Myeloma Cells upon Treatment with Lenalidomide and Proteasome Inhibitor. Blood, 2016, 128, 3281-3281.	1.4	1
122	Multi-Drug Resistant Organisms Are Common in Fecal Surveillance Cultures and Do Not Predict Bacteremia but Correlate with Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplants. Blood, 2016, 128, 3406-3406.	1.4	0
123	Second Hematopoietic SCT for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan Based Conditioning Regimen. Blood, 2016, 128, 2201-2201.	1.4	0
124	Role of Pre-Transplant Cardiac and Hepatic T2* Magnetic Resonance for Risk Assessment in Patients with Thalassemia Major Undergoing an Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 2200-2200.	1.4	0
125	Acute myeloid leukaemia: challenges and real world data from India. British Journal of Haematology, 2015, 170, 110-117.	2.5	96
126	Leukocyte derived chemotaxin 2 (ALECT2) amyloidosis. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015043.	1.3	12

#	Article	IF	CITATIONS
127	RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics, 2015, 16, 877-890.	1.3	41
128	Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. Annals of Hematology, 2015, 94, 883-885.	1.8	9
129	Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 3.	0.2	16
130	De-escalation of treatment for acute promyelocytic leukaemia?. Lancet Haematology,the, 2015, 2, e348-e349.	4.6	2
131	Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score. Blood, 2015, 126, 2620-2620.	1.4	1
132	Population Pharmacokinetics of Fludarabine and Treosulfan in Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 3120-3120.	1.4	6
133	Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance. PLoS ONE, 2015, 10, e0121912.	2.5	43
134	DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies. Oncotarget, 2015, 6, 32494-32508.	1.8	4
135	Mesenchymal stromal stem cell therapy in advanced interstitial lung disease - Anaphylaxis and short-term follow-up. Lung India, 2015, 32, 486.	0.7	3
136	Efficacy of stem cell in improvement of left ventricular function in acute myocardial infarction - MI3 Trial. Indian Journal of Medical Research, 2015, 142, 165.	1.0	17
137	V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia. Indian Journal of Pathology and Microbiology, 2015, 58, 62.	0.2	1
138	Coagulopathy in Acute Promyelocytic Leukemia: Strategies to Improve Assessment of Hemostatic Risk. Blood, 2015, 126, 3758-3758.	1.4	0
139	Donor Lymphocyte Infusion in Patients with Thalassemia Major Who Have Mixed Chimerism Following Allogeneic Stem Cell Transplant. Blood, 2015, 126, 1965-1965.	1.4	1
140	Generic Intravenous Busulfan in Hematopoietic Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring. Blood, 2015, 126, 4322-4322.	1.4	1
141	Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience. Blood, 2015, 126, 4386-4386.	1.4	1
142	Role of NF-E2 Related Factor 2 (NRF2) on Chemotherapy Resistance in Acute Myeloid Leukemia (AML) and the Effect of Pharmacological Inhibition of NRF2. Blood, 2015, 126, 1272-1272.	1.4	1
143	Efficacy of Second Line Agents Dapsone & Azathioprine in Children & Adults with Immune Thrombocytopenia: Single Centre Experience from India. Blood, 2015, 126, 1064-1064.	1.4	1
144	Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers. Blood, 2015, 126, 928-928.	1.4	0

#	Article	IF	CITATIONS
145	Adult Acute Lymphoblastic Leukemia: A Cost Effective Strategy and Limitations of Intensification of Therapy in India. Blood, 2015, 126, 3732-3732.	1.4	0
146	Generic Imatinib: The real-deal or just a deal?. Leukemia and Lymphoma, 2014, , 1-8.	1.3	4
147	NovelNPM1mutation in the 3'-untranslated region identified in two patients with acute myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 1421-1424.	1.3	1
148	Generic imatinib: the real-deal or just a deal?. Leukemia and Lymphoma, 2014, 55, 2678-2680.	1.3	13
149	Allogeneic Stem Cell Transplantation for Thalassemia Major. Hematology/Oncology Clinics of North America, 2014, 28, 1187-1200.	2.2	22
150	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24â€month followâ€up. American Journal of Hematology, 2014, 89, 732-742.	4.1	102
151	ABCB6 RNA expression in leukemias—expression is low in acute promyelocytic leukemia and FLT3-ITD-positive acute myeloid leukemia. Annals of Hematology, 2014, 93, 509-512.	1.8	6
152	Outcome of treatment with a low cost protocol in adults with T cell acute lymphoblastic leukemia in a tertiary care center in India. Leukemia and Lymphoma, 2014, 55, 947-949.	1.3	8
153	Association of growth differentiation factor 15 (GDF15) polymorphisms with serum GDF15 and ferritin levels in β-thalassemia. Annals of Hematology, 2014, 93, 2093-2095.	1.8	12
154	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
155	Clinical and Molecular Characterization of Fanconi Anemia: An Indian Perspective. Blood, 2014, 124, 2938-2938.	1.4	3
156	Arsenic Trioxide Resistance: More to It Than Mutations in PML-RARα. Blood, 2014, 124, 3605-3605.	1.4	4
157	Acute Myeloid Leukemia: Challenges and Real World Data from India. Blood, 2014, 124, 3685-3685.	1.4	7
158	Population Pharmacokinetics of Daunorubicin in AML: Influence on Clinical Outcome. Blood, 2014, 124, 902-902.	1.4	0
159	Proteasome Activity Is Dispensable for the Degradation of PML-RARα: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia. Blood, 2014, 124, 3741-3741.	1.4	0
160	The Addition of Meloxicam to G-CSF Is Associated with Good Mobilization Rates, Faster Engraftment and Reduced Toxicity and Hospital Stay after Autologous Stem Cell Transplantation – a Phase II Study. Blood, 2014, 124, 2455-2455.	1.4	0
161	Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India. Blood, 2014, 124, 2462-2462.	1.4	0
162	Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 3884-3884.	1.4	0

#	Article	IF	CITATIONS
163	The use of a fludarabineâ€based conditioning regimen in patients with severe aplastic anemia – a retrospective analysis from three <scp>I</scp> ndian centers. Clinical Transplantation, 2013, 27, 923-929.	1.6	19
164	Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. Journal of Dermatological Treatment, 2013, 24, 481-483.	2.2	14
165	Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. PLoS ONE, 2013, 8, e61637.	2.5	78
166	Harnessing Gene Expression Profiling In Search Of New Candidate Genes For Ara-C Resistance In Acute Myeloid Leukemia. Blood, 2013, 122, 1299-1299.	1.4	2
167	NPM1 Mutated AML Is Associated With Lower Expression Of Poor Prognostic Markers BAALC, ERG and MN1 In Adult Patients With Acute Myeloid Leukaemia. Blood, 2013, 122, 4945-4945.	1.4	1
168	Delay In Onset Of First Transfusion and Increased Risk Of Graft Rejection In β Thalassemia Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant. Blood, 2013, 122, 701-701.	1.4	0
169	Clinical Profile and Outcome Of Patients With Graft Rejection Following Related HLA Matched Allogeneic Stem Cell Transplant For β Thalassemia Major. Blood, 2013, 122, 4546-4546.	1.4	0
170	pVAX14 DNA, a Non-Specific DNA Vaccine, Improves Survival In An Acute Promyelocytic Leukemia (APL) Mouse Model Treated With All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) and Targets Leukemia Initiating Cells (LICs). Blood, 2013, 122, 235-235.	1.4	0
171	Expression Profiling Of Nuclear Hormone Receptors In Myeloid Leukemia Reveals Potential Novel Drug Targets For Combination Therapy. Blood, 2013, 122, 3855-3855.	1.4	1
172	Pharmacokinetics Of a Generic Formulation Of Intravenous Busulfan (BUCELON 60â,,¢) In Patients Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 3280-3280.	1.4	0
173	NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance. Blood, 2013, 122, 1455-1455.	1.4	12
174	Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. Leukemia and Lymphoma, 2012, 53, 103-109.	1.3	19
175	Clinicopathological features of hepatosplenic T cell lymphoma: a single centre experience from India. Leukemia and Lymphoma, 2012, 53, 609-615.	1.3	11
176	Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Blood, 2012, 119, 3413-3419.	1.4	45
177	Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics, 2012, 13, 269-282.	1.3	43
178	Polymorphisms in the Immunoregulatory Genes are Associated with Hematopoietic Recovery and Increased Susceptibility to Bacterial Infections in Patients with Thalassaemia Major Undergoing Matched Related Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1219-1226.	2.0	6
179	International Reporting Scale of <i>BCR-ABL1</i> Fusion Transcript in Chronic Myeloid Leukemia: First Report from India. Acta Haematologica, 2012, 127, 135-142.	1.4	8
180	Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. European Journal of Clinical Pharmacology, 2012, 68, 1577-1586.	1.9	29

#	Article	IF	CITATIONS
181	Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. Cytometry Part B - Clinical Cytometry, 2012, 82B, 252-258.	1.5	36
182	A novel δ-globin gene mutation (HBD: c.323G>A) masking the diagnosis of β-thalassemia: a first report from India. International Journal of Hematology, 2012, 95, 570-572.	1.6	12
183	Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update. Blood, 2012, 120, 3779-3779.	1.4	2
184	Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis. Indian Journal of Pathology and Microbiology, 2012, 55, 347.	0.2	7
185	RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia Blood, 2012, 120, 2785-2785.	1.4	Ο
186	A Phase II Study Using Post-Transplant Cyclophosphamide (PTC) As Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergoing HLA Matched Sibling Donor Stem Cell Transplant (SCT) for Severe Aplastic Anemia (SAA). Blood, 2012, 120, 4199-4199.	1.4	0
187	Community Based Evaluation of Prevalence of Inhibitors in Patients with Severe Hemophilia A in India and Their Correlation with Environmental and Genetic Factors. Blood, 2012, 120, 3380-3380.	1.4	0
188	Clinical Profile and Outcomes of Patients with β Thalassemia Major and Hepatitis C Virus Infection Undergoing an Allogeneic Stem Cell Transplant. Blood, 2012, 120, 4160-4160.	1.4	27
189	Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients. Blood, 2012, 120, 3607-3607.	1.4	Ο
190	ABC Transporter Expression in Acute Myeloid Leukemia: Association with in Vitro Cytotoxicity and Prognostic Markers. Blood, 2012, 120, 1438-1438.	1.4	0
191	Genetic Diagnosis of Inherited Bleeding Disorders in 1250 Probands From India: A Single Centre Experience. Blood, 2012, 120, 1127-1127.	1.4	Ο
192	Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors. Blood, 2012, 120, 1446-1446.	1.4	2
193	High Expression of p53 and Growth Differentiation Factor-15 in Beta-Thalassemia Blood, 2012, 120, 2130-2130.	1.4	0
194	Patterns of Immune Reconstitution in Patients with Acute Promyelocytic Leukemia Treated with Single Agent Arsenic Trioxide and Its Impact On Time to Molecular Remission. Blood, 2012, 120, 3552-3552.	1.4	0
195	Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance. Blood, 2012, 120, 1390-1390.	1.4	8
196	Molecular basis of hereditary factor V deficiency in India: Identification of four novel mutations and their genotype-phenotype correlation. Thrombosis and Haemostasis, 2011, 105, 1120-1123.	3.4	4
197	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011056.	1.3	39
198	Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT. Blood, 2011, 118, 1941-1941.	1.4	1

#	Article	IF	CITATIONS
199	Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 2011, 118, 426-426.	1.4	1
200	Response to Immunosuppressive Therapy with Antithymocyte Globulin (ATG) In Older Patients with Aplastic Anemia. Blood, 2011, 118, 4374-4374.	1.4	0
201	Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Under Going a HLA Matched Related Allogeneic Stem Cell Transplant with the Use of a Treosulphan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. Blood, 2011, 118, 1017-1017.	1.4	0
202	Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with Denovo AML,. Blood, 2011, 118, 3481-3481.	1.4	0
203	Carbonyl Reductase 1 Expression and Polymorphisms Influence Daunorubicin Metabolism in AML. Blood, 2011, 118, 2484-2484.	1.4	0
204	Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data. Blood, 2011, 118, 947-947.	1.4	0
205	Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy. Blood, 2011, 118, 941-941.	1.4	Ο
206	Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. Medical Oncology, 2010, 27, 1046-1049.	2.5	25
207	Clinical manifestations of combined factor V and VIII deficiency: A series of 37 cases from a single center in India. American Journal of Hematology, 2010, 85, 538-539.	4.1	15
208	Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data. Journal of Clinical Oncology, 2010, 28, 3866-3871.	1.6	235
209	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS SUPERIOR TO IMMUNOSUPPRESSIVE THERAPY IN INDIAN CHILDREN WITH APLASTIC ANEMIA—A SINGLE-CENTER ANALYSIS OF 100 PATIENTS. Pediatric Hematology and Oncology, 2010, 27, 122-131.	0.8	26
210	The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. Cancer Genetics and Cytogenetics, 2010, 203, 297-302.	1.0	27
211	Dendritic Cell Count in the Graft Predicts Relapse in Patients with Hematologic Malignancies Undergoing an HLA-Matched Related Allogeneic Peripheral Blood Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2010, 16, 854-860.	2.0	20
212	Trough Level of First Dose of Busulfan (Cmin1) Is a Stronger Predictor of Graft Rejection Than Steady State Concentration (Css1) In Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2010, 116, 518-518.	1.4	1
213	Allogeneic Transplant In Children with Severe Aplastic Anemia – Excellent Outcomes with the Use of a Fludarabine Based Conditioning Regimen. Blood, 2010, 116, 3519-3519.	1.4	Ο
214	Evaluation of Mechanisms of Resistance to Arsenic Trioxide In Patients with Acute Promyelocytic Leukemia. Blood, 2010, 116, 2746-2746.	1.4	0
215	A Polymorphism In Interferon Gamma Gene Impacts the Extent of Joint Damage In Patients with Severe Hemophilia. Blood, 2010, 116, 546-546.	1.4	1
216	Spectrum of <i>BCR-ABL</i> kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Leukemia and Lymphoma, 2009, 50, 2092-2095.	1.3	22

#	Article	IF	CITATIONS
217	Management of Hemophilia in Patients with Inhibitors: The Perspective from Developing Countries. Seminars in Thrombosis and Hemostasis, 2009, 35, 820-826.	2.7	20
218	Fludarabineâ€based reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with aplastic anemia and fungal infections. Clinical Transplantation, 2009, 23, 228-232.	1.6	14
219	Impact of pretransplant splenectomy on patients with βâ€ŧhalassemia major undergoing a matchedâ€related allogeneic stem cell transplantation. Pediatric Transplantation, 2009, 13, 171-176.	1.0	18
220	Cellular Immune Reconstitution and Its Impact on Clinical Outcome in Children with β Thalassemia Major Undergoing a Matched Related Myeloablative Allogeneic Bone Marrow Transplant. Biology of Blood and Marrow Transplantation, 2009, 15, 597-609.	2.0	19
221	Comparison of Clinical Outcomes of Patients with Relapsed Acute Promyelocytic Leukemia Induced with Arsenic Trioxide and Consolidated with Either an Autologous Stem Cell Transplant or an Arsenic Trioxide–Based Regimen. Biology of Blood and Marrow Transplantation, 2009, 15, 1479-1484.	2.0	84
222	Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassaemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation Blood, 2009, 114, 1182-1182.	1.4	2
223	A Fludarabine Based Conditioning Regimen Associated with A Good Survival Following HLA Identical Sibling/Family Donor Transplants in Patients with Aplastic Anemia Blood, 2009, 114, 1194-1194.	1.4	1
224	Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04) Blood, 2009, 114, 2082-2082.	1.4	2
225	Risk Stratification without a Liver Biopsy of Patients with β Thalassemia Major Undergoing a Matched Related Allogeneic Bone Marrow Transplant Blood, 2009, 114, 659-659.	1.4	11
226	Polymorphisms in the CYP450 Genes Influences Regimen Related Toxicity and Outcome in Patients with Beta Thalassaemia Major Undergoing HSCT Blood, 2009, 114, 869-869.	1.4	2
227	Population Pharmacokinetics of Busulfan in Patients with Beta Thalassaemia Major Undergoing HSCT Reveals Body Weight, GSTA1 and CYP3A4 Promoter Polymorphisms as Main Covariates Explaining the Inter-Individual Variation Blood, 2009, 114, 3349-3349.	1.4	0
228	Comparison of Differential Gene Expression Profiles of Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide with the Profile of An Arsenic Trioxide Resistant NB4 Cell Line Blood, 2009, 114, 3460-3460.	1.4	0
229	Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long Term Follow-up Data Blood, 2009, 114, 846-846.	1.4	0
230	Fluorescent PCR Based Gene Dose Assessment for Detection of Deletion Mutations in the FIX Gene Among Carriers of Hemophilia B Blood, 2009, 114, 3486-3486.	1.4	0
231	Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatric Blood and Cancer, 2008, 51, 621-625.	1.5	48
232	Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia. Pediatric Transplantation, 2008, 12, 14-19.	1.0	32
233	Plasmacytoid Dendritic Cell Count on Day 28 in HLA-Matched Related Allogeneic Peripheral Blood Stem Cell Transplant Predicts the Incidence of Acute and Chronic GVHD. Biology of Blood and Marrow Transplantation, 2008, 14, 344-350.	2.0	35
234	Three siblings with Woodhouse–Sakati syndrome in an Indian family. Clinical Dysmorphology, 2008, 17, 57-60.	0.3	30

#	Article	IF	CITATIONS
235	Risk factors of thrombosis in abdominal veins. World Journal of Gastroenterology, 2008, 14, 4518.	3.3	18
236	Minimal Residual Disease Monitoring in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with Arsenic Trioxide. Blood, 2008, 112, 2534-2534.	1.4	0
237	Increased ABCG2 Expression Could Be Responsible for Resistance to Imatinib Mesylate in Patients with Chronic Myeloid Leukemia Who Do Not Have Mutations in BCR-ABL Kinase Domain. Blood, 2008, 112, 5026-5026.	1.4	53
238	Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica, 2007, 92, 994-995.	3.5	54
239	A New Stratification Strategy That Identifies a Subset of Class III Patients with an Adverse Prognosis among Children with β Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 889-894.	2.0	67
240	Bone Marrow Transplantation for β Thalassemia Major: Long Term Experience from a Single Centre in India Blood, 2007, 110, 1106-1106.	1.4	1
241	Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and Cyclophosphamide for High Risk Patients with Thalassemia Major Undergoing Allogeneic Bone Marrow Transplantation Results in High Rejection Rates Blood, 2007, 110, 1998-1998.	1.4	2
242	Pharmacokinetic and Pharmacodynamic Evaluation of a Biosimilar Rituximab in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP (Rituximab, Cyclophosphamide, Adriamycin,) Tj E1	QqΩ40 0 r	gBѢ/Overlock
243	Fludarabine and Melphalan Conditioning Regimen in Young Patients with Acute Myeloid Leukemia in CR1 Undergoing a Matched Related Allogeneic Stem Cell Transplant: A Single Center Experience Blood, 2007, 110, 5049-5049.	1.4	1
244	Treatment of Relapsed and Refractory Acute Myeloid Leukemia with a Salvage FLAG-IDA Chemotherapy Regimen Followed by a HLA Matched Related Allogeneic PBSC Infusion without Additional Conditioning Blood, 2007, 110, 5050-5050.	1.4	1
245	Analysis of β Globin Mutations in the Indian Population: Presence of Rare and Novel Mutations and Region Wise Heterogeneity Blood, 2007, 110, 3822-3822.	1.4	Ο
246	C-CSF Primed Bone Marrow Is Not Superior to Unprimed Bone Marrow as a Source of Stem Cells in HLA Matched Related Allogeneic SCT for β Thalassaemia Major Blood, 2007, 110, 5052-5052.	1.4	0
247	Polymorphism in the IFN-Î ³ Gene Is Associated with Severe Acute Graft Versus Host Disease in Î ² Thalassemia Major Patients Undergoing Matched Related Hematopoietic Stem Cell Transplantation (HSCT) Blood, 2007, 110, 1105-1105.	1.4	3
248	Molecular Analysis of WASP Gene - First Report from India Blood, 2007, 110, 3217-3217.	1.4	0
249	Comparison of Clinical Outcomes of Relapsed APL Patients Induced with ATO and Consolidated with Either an Autologous SCT or ATO Based Treatment Regimen Blood, 2007, 110, 2880-2880.	1.4	7
250	Kinetics of Molecular Response among Newly Diagnosed Patients with PML-RARα+ Acute Promyelocytic Leukemia Treated with Arsenic Trioxide Blood, 2007, 110, 4366-4366.	1.4	0
251	Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood, 2006, 107, 2627-2632.	1.4	313
252	Infections in children undergoing allogeneic bone marrow transplantation in India. Pediatric Transplantation, 2006, 10, 48-54.	1.0	34

#	Article	IF	CITATIONS
253	Identification of Candidate Alkylator-Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice. Cancer Research, 2006, 66, 5029-5038.	0.9	44
254	Dendritic Cell Type 2 Counts on Day 28 in HLA-Matched Related Allogeneic PBSCT Predicts the Incidence of Acute and Chronic GVHD Blood, 2006, 108, 2893-2893.	1.4	8
255	A Low Intensity Protocol of Fludarabine, Busulfan and Cyclophosphamide Reduces Toxicity without Compromising Engraftment in Children Undergoing Allogeneic Bone Marrow Transplantation for Beta Thalassaemia Major Blood, 2006, 108, 5366-5366.	1.4	0
256	Two Mutations (1717 T〉C, GP IX;124del145, GPIb beta) Occur Frequently among Patients with Bernard Soulier Syndrome in India Blood, 2006, 108, 1096-1096.	1.4	0
257	Polymorphisms in Coagulant and Inflammatory Genes Modify the Phenotype of Severe Hemophilia A and B Blood, 2006, 108, 1009-1009.	1.4	3
258	Il-10 Polymorphism and TGF-β Haplotypes Are Associated with Rejection of Graft in Children with Beta Thalassemia Major Undergoing Matched Related Bone Marrow Transplantation (BMT) Blood, 2006, 108, 3011-3011.	1.4	0
259	Impact of Additional Cytogenetic Changes and FLT3 Mutations on the Outcome of Patients with Newly Diagnosed Acute Promyelocytic Leukaemia Treated with Single Agent Arsenic Trioxide Blood, 2006, 108, 2346-2346.	1.4	Ο
260	A New Stratification Strategy That Identifies a Subset of Class III Patients among Children with β Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell Transplantation Blood, 2006, 108, 2996-2996.	1.4	0
261	Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults – a report on 90 patients. European Journal of Haematology, 2005, 75, 328-331.	2.2	57
262	Surgery for Hemophilia in Developing Countries. Seminars in Thrombosis and Hemostasis, 2005, 31, 538-543.	2.7	25
263	Developing an Algorithm for Monitoring Chimerism after Allogeneic Bone Marrow Transplantation - A Single Centre Experience Blood, 2005, 106, 5301-5301.	1.4	0
264	Durable Remissions with Single Agent As2O3 in the Treatment of Newly Diagnosed Cases of Acute Promyelocytic Leukemia: Risk Stratification within This Group and Potential Impact on Future Algorithms Blood, 2005, 106, 892-892.	1.4	0
265	Surveyorâ"¢ Nuclease: A New Rapid and Effective Strategy for Detection of Single Nucleotide Changes in Alpha Globin Genes Blood, 2005, 106, 3653-3653.	1.4	0
266	A Pilot Study of Rabbit Antithymocyte Globulin - TECELAC Combined with Cyclosporine and Prednisolone as Immunosuppressive Therapy for Severe Aplastic Anemia Blood, 2005, 106, 3749-3749.	1.4	0
267	Oral Prednisolone Produces a Durable Response in Pediatric Myelodysplastic Syndromes (MDS) Blood, 2005, 106, 4906-4906.	1.4	0
268	The Role of Donor Lymphocyte Infusion (DLI) and Imatinib Mesylate in the Treatment of Relapse after Allogenic Stem Cell Transplant for Chronic Myeloid Leukemia Blood, 2005, 106, 5393-5393.	1.4	0
269	Fludarabine Based Conditioning for Allogeneic Transplantation in Severe Aplastic Anemia Blood, 2005, 106, 2029-2029.	1.4	0
270	Imatinib in India: Is the efficacy universal?. Indian Journal of Medical and Paediatric Oncology, 2005, 26, 3-4.	0.2	1

#	Article	IF	CITATIONS
271	Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15184-15189.	7.1	81
272	Recruitment of Bone Marrow-Derived Endothelial Cells to Sites of Pancreatic Â-Cell Injury. Diabetes, 2004, 53, 91-98.	0.6	172
273	Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood, 2004, 104, 1574-1577.	1.4	155
274	Arsenic Trioxide (As2O3) in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APML) - Toxicity and Outcome Blood, 2004, 104, 889-889.	1.4	21
275	Six Novel Mutations Including Triple Heterozygosity for Phe31Ser, 514delT and 516T→G Mutations in Factor X Gene Is Responsible for Congenital Factor X Deficiency in Patients of Indian and Nepali Origin Blood, 2004, 104, 1042-1042.	1.4	6
276	Pharmacogenetics of Cyclophosphamide in Patients with Beta Thalassemia Major Undergoing Bone Marrow Transplantation Blood, 2004, 104, 99-99.	1.4	0
277	Molecular Genetics of Hereditary Prothrombin Deficiency in Indian Patients: Identification of a Novel Ala362→Thr (Prothrombin Vellore 1) Mutation by Conformation Sensitive Gel Electrophoresis Blood, 2004, 104, 1037-1037.	1.4	0
278	Cyclophosphamide Kinetics Influences Toxicity and Outcome of Bone Marrow Transplantation in Patients with β-Thalassemia Major Blood, 2004, 104, 1820-1820.	1.4	0
279	Enhanced green fluorescent protein targeted to the Sca-1 (Ly-6A) locus in transgenic mice results in efficient marking of hematopoietic stem cells in vivo. Experimental Hematology, 2003, 31, 159-167.	0.4	47
280	Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experience. American Journal of Hematology, 2002, 70, 292-299.	4.1	63
281	Polymyositis - an unusual manifestation of chronic graft-versus-host disease. Rheumatology International, 2001, 20, 169-170.	3.0	20
282	Cyclophosphamide induced haemorrhagic myocarditis-pericarditis: a rare but lethal complication in the setting of allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	2.4	1